985. Impact of Age and Medical Comorbidities on Renal Outcomes in the DISCOVER Trial

BACKGROUND: In DISCOVER, emtricitabine/tenofovir alafenamide (F/TAF) was noninferior to F/tenofovir disoproxil fumarate (TDF) for preexposure prophylaxis (PrEP) in men who have sex with men and transgender women, with a superior renal laboratory profile. The differential impact of F/TAF and F/TDF on...

Descripción completa

Detalles Bibliográficos
Autores principales: Daar, Eric, Brunetta, Jason, Cua, Eric, Flamm, Jason, Asmuth, David, Carter, Christoph C, Shao, Yongwu, Wong, Pamela, Ebrahimi, Ramin, Das, Moupali, Brainard, Diana M, Clarke, Amanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776228/
http://dx.doi.org/10.1093/ofid/ofaa439.1171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776228/
http://dx.doi.org/10.1093/ofid/ofaa439.1171

Ejemplares similares